➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
McKesson
Medtronic
Moodys
Harvard Business School

Last Updated: August 6, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OTEZLA

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Otezla

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00521339 Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis Completed Celgene Corporation Phase 2 2007-08-01 The study will test the safety and tolerability of Apremilast twice a day in participants with recalcitrant plaque type psoriasis.
NCT00773734 Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study) Completed Celgene Corporation Phase 2 2008-09-01 The purpose of this study was to test if the drug apremilast was safe, if it helped improve psoriasis, and how well the participants tolerated it.
NCT00866359 A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease Completed Celgene Corporation Phase 2 2009-10-01 The purpose of this study is to assess whether Apremilast is safe and effective in the treatment of patients with Behcet Disease.
NCT01194219 Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis Active, not recruiting Celgene Corporation Phase 3 2010-09-01 This study evaluated the effects of an called apremilast. Apremilast works by lowering some of the chemicals that affect psoriasis and therefore improves the symptoms of psoriasis. The purpose of this study was to test apremilast and compare its effects to placebo (an inactive substance which contains no medicine but is in the same form as the drug). This study was able to test for efficacy (improvement of signs and symptoms) and safety of apremilast in patients with moderate to severe psoriasis.
NCT01232283 Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis. Active, not recruiting Celgene Corporation Phase 3 2010-11-01 This study will evaluate the effects of an experimental (being tested) study drug called apremilast. Apremilast works by lowering some of the chemicals that affect psoriasis and therefore improves the symptoms of psoriasis. The purpose of this study is to test apremilast and compare its effects to placebo (an inactive substance which contains no medicine but is in the same form as the drug). This study will test efficacy (improvement of signs and symptoms) and safety of apremilast in patients with moderate to severe psoriasis.
NCT01285310 Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis Terminated Celgene Corporation Phase 2 2010-12-01 The purpose of this study is to determine whether Apremilast is safe and effective in the treatment of patients with rheumatoid arthritis, specifically in improving signs and symptoms of rheumatoid arthritis (tender and swollen joints, pain, physical function and structure) in treated patients who have had an inadequate response to Methotrexate.
NCT01690299 Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis Completed Celgene Corporation Phase 3 2012-10-01 This study will test the clinical effectiveness and safety of apremilast compared with placebo as well as etanercept compared with placebo in the same group of patients with moderate to severe plaque psoriasis. Apremilast (CC-10004) is a new oral agent that is under clinical development for the treatment of inflammatory autoimmune disorders, such as psoriatic arthritis, psoriasis, rheumatoid arthritis, and Behçet disease. Etanercept is approved for the treatment of psoriasis; it is the most widely prescribed anti-tumor necrosis factor (TNF) for psoriasis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Otezla

Condition Name

Condition Name for Otezla
Intervention Trials
Plaque Psoriasis 8
Psoriasis 5
Psoriatic Arthritis 4
Behcet Syndrome 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Otezla
Intervention Trials
Psoriasis 16
Arthritis 6
Arthritis, Psoriatic 5
Dermatitis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Otezla

Trials by Country

Trials by Country for Otezla
Location Trials
United States 155
Canada 37
Australia 11
Germany 5
France 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Otezla
Location Trials
California 12
Florida 11
Illinois 8
Texas 8
New York 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Otezla

Clinical Trial Phase

Clinical Trial Phase for Otezla
Clinical Trial Phase Trials
Phase 4 13
Phase 3 6
Phase 2 12
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Otezla
Clinical Trial Phase Trials
Recruiting 11
Not yet recruiting 9
Completed 8
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Otezla

Sponsor Name

Sponsor Name for Otezla
Sponsor Trials
Celgene Corporation 18
Celgene 8
Psoriasis Treatment Center of Central New Jersey 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Otezla
Sponsor Trials
Industry 29
Other 21
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Moodys
Merck
Mallinckrodt
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.